|Mr. Mitsuo Sawai||Pres & Representative Director||N/A||N/A||N/A|
|Mr. Kazuhiko Sueyoshi||Managing Exec. Officer, Director of Fin., GM of Admin. Headquarters & Director||N/A||N/A||N/A|
|Mr. Toru Terashima||Sr. Exec. Officer, VP of Reliability Assurance Div., Gen. Marketing Compliance Officer & Director||N/A||N/A||N/A|
|Mr. Akira Hamada||Sr. Exec. Officer & GM of HR Department||N/A||N/A||N/A|
|Mr. Kenzo Sawai||Sr. Managing Exec. Officer, GM of Strategic Planning Department & Director||N/A||N/A||N/A|
Sawai Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceutical products. It offers drugs in various formulations, including tablets, oral dispersing tablets, capsules, granules, injections, tapes, ophthalmic/nasal solutions, syrups, etc. in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, chemotherapeutics, vitamins, anti-cancer, etc. The company serves hospitals, general practitioners, and dispensing pharmacies. It has operations in Japan and the United States. The company was founded in 1929 and is headquartered in Osaka, Japan.
Sawai Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of December 5, 2019 is 8. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 3; Compensation: 8.